OBJECTIVE: To probe into the effects of clopidogrel combined with atorvastatin on fibrinolysis status and cardiac function in patients with angina pectoris of coronary heart disease (CHD). METHODS: Totally 116 patients with angina pectoris of CHD admitted into Henan Tanghe County People's Hospital from Oct. 2016 to Oct. 2017 were extracted to be divided into observation group and control group via the random number table, with 58 cases in each group. Patients in the control group were given conventional drug therapy, while the observation group received clopidogrel and atorvastatin on the basis of the control group. The clinical efficacy, number and duration of angina attacks, tissue plasminogen activator inhibitor 1 (tPAI-1), soluble E-selectin (sE-selectin), ejection fraction (EF), cardiac index (CI) before and after treatment and adverse drug reactions were observed. RESULTS: The total effective rate of the observation group was 93.10％ (54/58), significantly higher than that of the control group (77.59％, 45/58), with statistically significant difference (P＜0.05). After treatment, the number and duration of angina attacks in the observation group were significantly better than those in the control group, with statistically significant differences (P＜0.05). After treatment, the tPAI-1 and sE-selectin levels in the observation group were significantly lower than those in the control group, and the EF and CI levels were significantly higher than those in the control group, with statistically significant differences (P＜0.05). The incidence of adverse drug reactions in the observation group and the control group was 5.17％ (3/58) and 8.62％ (5/58), respectively, with no statistically significant difference (P＞0.05). CONCLUSIONS: The efficacy of clopidogrel combined with atorvastatin in treatment of angina pectoris of CHD is remarkable, which can correct the symptoms of angina pectoris, help to regulate the state of fibrinolysis and improve the heart function with higher safety.%目的:探讨氯吡格雷联合阿托伐他汀对冠心病心绞痛患者纤溶状态及心功能的影响.方法:选取2016年10月至2017年10月河南省唐河县人民医院收治的冠心病心绞痛患者116例, 采用随机数字表法分为观察组和对照组, 每组58例.对照组患者给予常规药物治疗, 观察组患者在对照组的基础上加用氯吡格雷、阿托伐他汀治疗.观察两组患者的临床疗效, 治疗前后的心绞痛发作次数、持续时间、组织型纤溶酶原激活物抑制剂1 (tPAI-1) 、可溶性E-选择素 (sE-selectin) 、射血分数 (EF) 、心脏指数 (CI) 及不良反应发生情况.结果:观察组患者的总有效率为93.10％ (54/58), 明显高于对照组的77.59％ (45/58), 差异有统计学意义 (P＜0.05);治疗后, 观察组患者的心绞痛发作次数、持续时间明显优于对照组, 差异均有统计学意义 (P＜0.05);治疗后, 观察组患者tPAI-1、sE-selectin水平明显低于对照组, EF、CI水平明显高于对照组, 差异均有统计学意义 (P＜0.05);观察组、对照组患者不良反应发生率分别为5.17％ (3/58) 、8.62％ (5/58), 差异无统计学意义 (P＞0.05).结论:氯吡格雷联合阿托伐他汀治疗冠心病心绞痛的疗效显著, 可纠正患者心绞痛症状, 有利于调节纤溶状态, 改善心功能, 且安全性较高.
展开▼
